Wegovy vs Zepbound vs Mounjaro: Which GLP-1 Is Worth Your Money in 2026?

TL;DR

The honest answer: Tirzepatide wins on raw weight loss numbers. Wegovy wins on cardiovascular outcomes and cash-pay affordability. Neither is “better” in isolation — your medical history should drive the choice.

Introduction

You’ve probably heard the hype. GLP-1 medications are being called everything from “miracle drugs” to “the end of obesity.” But if you’re actually considering one — or trying to decide between the two biggest names — the noise makes the decision harder, not easier.

Here’s what most articles won’t tell you: the “best” GLP-1 doesn’t exist in a vacuum. Tirzepatide produces more weight loss on average. Semaglutide has the cardiovascular data. One costs less at the starting dose. The other costs less at maintenance for some patients. And your insurance — or lack thereof — may make the entire comparison academic.

This article isn’t here to sell you a medication. It’s here to answer the five questions that actually matter before you spend $150 to $450 a month on a prescription that you’ll need to keep taking to maintain results:

1. Why this one? What’s the actual mechanism difference?
2. Does it work? What does the clinical evidence show — not the marketing?
3. Is it safe? Side effects, contraindications, and titration.
4. What will it cost? Real 2026 numbers, not vague ranges.
5. What happens if I click? The process, eligibility, and next steps.

After 30+ years in clinical and hospital practice watching weight management treatments come and go, I can tell you this: the medications that work are the ones patients can actually tolerate, afford, and stay on. The rest is noise.

Let’s cut through it.

Pros & Cons

Tirzepatide (Zepbound / Mounjaro)

Pros:

• Greatest average weight loss among approved agents (~21–22% at 15mg)
• Higher proportion of patients achieving ≥15% and ≥20% weight loss thresholds
• Slightly lower discontinuation rate due to side effects in some analyses (6% vs 8%)
• Some evidence of heart failure reduction (~51%)

Cons:

• More expensive at cash-pay starting doses (~$299–$449/month)
• Reduced lean muscle mass more than semaglutide in one meta-analysis (8.3% vs comparable)
• Weaker cardiovascular outcome data compared to semaglutide’s comprehensive results
• Longer titration pathway to reach maintenance dose

Semaglutide (Wegovy)

Pros:

• Strongest cardiovascular evidence: 19% reduced all-cause death, 28% reduced heart attack, 20% reduced kidney disease progression
• Cheaper cash-pay entry (~$149/month for pill, $399 for high-dose injection)
• The only drug associated with reduced all-cause mortality in one major meta-analysis
• Oral formulation available (Wegovy pill) for needle-averse patients

Cons:

• Lower average weight loss at standard 2.4mg dose (~15–17%)
• New 7.2mg dose narrows the gap (~19–21%) but costs more
• Slightly higher discontinuation rate due to GI side effects in some comparisons
• Weight regain after stopping is well-documented

Key Features

Tirzepatide (Zepbound / Mounjaro)

Mechanism: Dual GIP and GLP-1 receptor agonist. It mimics two hormones — GLP-1 (which slows stomach emptying and signals fullness) and GIP (which affects fat storage and energy metabolism).

Dosing: Weekly injection. Titration typically starts at 2.5mg, escalates over weeks to a maintenance dose of 10mg or 15mg.

Weight loss data: 15mg over 72 weeks produced ~21.6% average body weight reduction in head-to-head data.

Safety profile: Most common side effects are gastrointestinal (nausea, vomiting, diarrhea, constipation). These occur during titration and typically improve. Contraindicated in MTC/MEN2 history and pregnancy.

Semaglutide (Wegovy)

Mechanism: GLP-1 receptor agonist only. Slows gastric emptying, reduces appetite signaling in the brain.

Dosing: Weekly injection. Titration from 0.25mg over 16 weeks to 2.4mg maintenance. A 7.2mg higher dose is now available at $399/month cash-pay.

Weight loss data: 2.4mg produced ~15.4% average reduction; 7.2mg produced ~19–21% in recent trials.

Safety profile: Similar GI side-effect pattern to tirzepatide. The key differentiator is the cardiovascular outcome data — semaglutide has demonstrated reductions in death, heart attack, and kidney disease progression in large trials.

Real Customer Experiences

Clinical experience (30+ years): The patients who do best on these medications are the ones who view them as one tool among several — not a magic bullet. The ones who struggle are those who expect the injection to do the work for them. Appetite suppression makes eating less easier, but it doesn’t make choosing better foods automatic. The muscle loss data is real and concerning — protein intake and resistance training aren’t optional if you want to lose fat, not just weight.

Who It’s Best For

Tirzepatide is likely a better fit if you:

• Have a BMI ≥30, or ≥27 with at least one weight-related condition (hypertension, type 2 diabetes, high cholesterol)
• Have tried and plateaued on semaglutide or another GLP-1
• Prioritize maximum weight reduction over cardiovascular risk modification
• Tolerated GLP-1 side effects reasonably well previously
• Have insurance coverage or can afford $299–$449/month cash-pay

Semaglutide is likely a better fit if you:

• Have established cardiovascular disease, prior heart attack, stroke, or kidney disease
• Need the lowest cash-pay entry point ($149/month for the pill)
• Have a history of GI sensitivity and want to start with the most extensively studied safety profile
• Prefer an oral option over injections
• Are on a tighter budget and need predictable monthly costs

Who Should Skip It

Do NOT take either medication if you have:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• A history of pancreatitis
• Are pregnant, planning pregnancy, or breastfeeding

Consider alternatives if you:

• Cannot tolerate GI side effects at even the lowest doses
• Have a history of eating disorders (appetite suppression can complicate recovery)
• Cannot commit to long-term use — weight regain after stopping is well-documented
• Are unwilling or unable to maintain adequate protein intake and some form of resistance training to mitigate lean muscle loss

Comparison Table

FAQs

Is Zepbound or Wegovy more effective for weight loss?

At maximum approved doses, tirzepatide (Zepbound/Mounjaro) produces greater average weight loss: ~21–22% vs ~15–17% for semaglutide 2.4mg. However, the newer Wegovy 7.2mg dose produces ~19–21%, narrowing the gap considerably.

Which is cheaper — Wegovy or Zepbound?

Wegovy tends to be cheaper at cash-pay entry: the pill starts at $149/month through NovoCare, while the high-dose injection is $399/month. Zepbound single-dose vials start at $299/month through LillyDirect. With commercial insurance and savings cards, both can drop as low as $25/month.

Does semaglutide protect the heart more than tirzepatide?

Current evidence favors semaglutide for cardiovascular protection. Subcutaneous semaglutide was associated with reduced all-cause death (19%), heart attack (28%), and kidney disease progression (20%) in a major meta-analysis. Tirzepatide showed some heart failure reduction but lacks the comprehensive cardiovascular outcome data.

Can I switch from Wegovy to Zepbound or vice versa?

Yes, but only under medical supervision. Switching typically involves a washout period or dose mapping, and you’ll need to re-titrate on the new medication. Never switch on your own.

What happens if I stop taking these medications?

Weight regain is common. Clinical trial data shows that weight loss achieved while on the medication is not sustained after stopping treatment without significant lifestyle changes. These are chronic-use medications for most patients.

Are the side effects different between the two?

Both share a similar GI side-effect profile (nausea, vomiting, diarrhea, constipation). Some meta-analyses show tirzepatide with slightly higher vomiting odds but lower overall discontinuation. The key difference is that semaglutide has the most robust long-term safety data given its longer time on market.

Do these medications cause muscle loss?

Yes. Tirzepatide reduced lean mass the most in one major meta-analysis (8.3%). This is a real concern and why adequate protein intake and resistance training are recommended during treatment.

Final Verdict

The honest answer: there is no universally “better” GLP-1.

Tirzepatide wins on the numbers most people care about first — pounds lost. If your primary goal is to lose as much weight as possible, and you can afford it, tirzepatide is the more potent option.

Semaglutide wins on the evidence that matters most for long-term health — cardiovascular outcomes. If you have heart disease risk factors, prior cardiac events, or kidney concerns, semaglutide has the data that tirzepatide currently lacks.

And then there’s the practical reality: cost and coverage often decide the winner before efficacy does. Wegovy’s cash-pay entry point is lower. Some insurance plans cover one but not the other. Manufacturer savings programs change the math entirely.

Before you buy, check:

1. Your insurance formulary — which medication is covered, at what tier?
2. Manufacturer savings programs — do you qualify? NovoCare and LillyDirect both offer direct pricing
3. Your cardiovascular risk profile — if you have cardiac history, that may tip the scale toward semaglutide
4. Your tolerance for GI side effects — both can cause them, and titration is gradual for a reason
5. Your willingness to commit long-term — these are not short-term fixes

Ready to explore your options?

Last updated: October 15, 2026. Prices and insurance coverage change frequently. Verify current pricing directly with the manufacturer or your pharmacy before making decisions. This article contains affiliate links. We only recommend products we believe may be relevant to readers based on clinical evidence and market availability.